The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women
<p>Abstract</p> <p>Background</p> <p>In the absence of head-to-head trials, indirect comparisons of randomized placebo-controlled trials may provide a viable option to assess relative efficacy. The purpose was to estimate the relative efficacy of reduction of fractures...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | BMC Musculoskeletal Disorders |
Online Access: | http://www.biomedcentral.com/1471-2474/12/209 |
id |
doaj-9626f3514ffb4cb5af5e66d087b9caee |
---|---|
record_format |
Article |
spelling |
doaj-9626f3514ffb4cb5af5e66d087b9caee2020-11-25T01:48:49ZengBMCBMC Musculoskeletal Disorders1471-24742011-09-0112120910.1186/1471-2474-12-209The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal womenPullenayegum EleanorGoeree RonHopkins Robert BAdachi Jonathan DPapaioannou AlexandraXie FengThabane Lehana<p>Abstract</p> <p>Background</p> <p>In the absence of head-to-head trials, indirect comparisons of randomized placebo-controlled trials may provide a viable option to assess relative efficacy. The purpose was to estimate the relative efficacy of reduction of fractures in post-menopausal women, and to assess robustness of the results.</p> <p>Methods</p> <p>A systematic literature review of multiple databases identified randomized placebo-controlled trials with nine drugs for post-menopausal women. Odds ratio and 95% credibility intervals for the rates of hip, non-vertebral, vertebral, and wrist fractures for each drug and between drugs were derived using a Bayesian approach. A drug was ranked as the most efficacious if it had the highest posterior odds ratio, or had the highest effect size.</p> <p>Results</p> <p>30 studies including 59,209 patients reported fracture rates for nine drugs: alendronate (6 studies), denosumab (1 study), etidronate (8 studies), ibandronate (4 studies), raloxifene (1 study), risedronate (7 studies), strontium (2 study), teriparatide (1 study), and zoledronic acid (1 study). The drugs with the highest probability of reducing non-vertebral fractures was etidronate and teriparatide while the drugs with the highest probability of reducing vertebral, hip or wrist fractures were teriparatide, zoledronic acid and denosumab. The drugs with the largest effect size for vertebral fractures were zoledronic acid, teriparatide and denosumab, while the drugs with the highest effect size for non-vertebral, hip or wrist fractures were alendronate or risedronate. Estimates were consistent between Bayesian and classical approaches.</p> <p>Conclusion</p> <p>Teriparatide, zoledronic acid and denosumab have the highest probabilities of being most efficacious for non-vertebral and vertebral fractures, and having the greatest effect sizes. The estimates from indirect comparisons were robust to differences in methodology.</p> http://www.biomedcentral.com/1471-2474/12/209 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pullenayegum Eleanor Goeree Ron Hopkins Robert B Adachi Jonathan D Papaioannou Alexandra Xie Feng Thabane Lehana |
spellingShingle |
Pullenayegum Eleanor Goeree Ron Hopkins Robert B Adachi Jonathan D Papaioannou Alexandra Xie Feng Thabane Lehana The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women BMC Musculoskeletal Disorders |
author_facet |
Pullenayegum Eleanor Goeree Ron Hopkins Robert B Adachi Jonathan D Papaioannou Alexandra Xie Feng Thabane Lehana |
author_sort |
Pullenayegum Eleanor |
title |
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women |
title_short |
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women |
title_full |
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women |
title_fullStr |
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women |
title_full_unstemmed |
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women |
title_sort |
relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women |
publisher |
BMC |
series |
BMC Musculoskeletal Disorders |
issn |
1471-2474 |
publishDate |
2011-09-01 |
description |
<p>Abstract</p> <p>Background</p> <p>In the absence of head-to-head trials, indirect comparisons of randomized placebo-controlled trials may provide a viable option to assess relative efficacy. The purpose was to estimate the relative efficacy of reduction of fractures in post-menopausal women, and to assess robustness of the results.</p> <p>Methods</p> <p>A systematic literature review of multiple databases identified randomized placebo-controlled trials with nine drugs for post-menopausal women. Odds ratio and 95% credibility intervals for the rates of hip, non-vertebral, vertebral, and wrist fractures for each drug and between drugs were derived using a Bayesian approach. A drug was ranked as the most efficacious if it had the highest posterior odds ratio, or had the highest effect size.</p> <p>Results</p> <p>30 studies including 59,209 patients reported fracture rates for nine drugs: alendronate (6 studies), denosumab (1 study), etidronate (8 studies), ibandronate (4 studies), raloxifene (1 study), risedronate (7 studies), strontium (2 study), teriparatide (1 study), and zoledronic acid (1 study). The drugs with the highest probability of reducing non-vertebral fractures was etidronate and teriparatide while the drugs with the highest probability of reducing vertebral, hip or wrist fractures were teriparatide, zoledronic acid and denosumab. The drugs with the largest effect size for vertebral fractures were zoledronic acid, teriparatide and denosumab, while the drugs with the highest effect size for non-vertebral, hip or wrist fractures were alendronate or risedronate. Estimates were consistent between Bayesian and classical approaches.</p> <p>Conclusion</p> <p>Teriparatide, zoledronic acid and denosumab have the highest probabilities of being most efficacious for non-vertebral and vertebral fractures, and having the greatest effect sizes. The estimates from indirect comparisons were robust to differences in methodology.</p> |
url |
http://www.biomedcentral.com/1471-2474/12/209 |
work_keys_str_mv |
AT pullenayegumeleanor therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT goereeron therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT hopkinsrobertb therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT adachijonathand therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT papaioannoualexandra therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT xiefeng therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT thabanelehana therelativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT pullenayegumeleanor relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT goereeron relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT hopkinsrobertb relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT adachijonathand relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT papaioannoualexandra relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT xiefeng relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen AT thabanelehana relativeefficacyofnineosteoporosismedicationsforreducingtherateoffracturesinpostmenopausalwomen |
_version_ |
1725009846977167360 |